XBIO Xenetic Biosciences, Inc. - Common Stock

NASDAQ · Biotechnology · View on SEC EDGAR ↗
$3.25
Price · Aug 18, 2026
Fundamentals as of Aug 6, 2026

About Xenetic Biosciences, Inc. - Common Stock Company overview from Wikipedia

XBIO Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

Price
$3.25
Market Cap
P/E (TTM)
-1.4
EPS (TTM)
$-1.58
Revenue (TTM)
$3M
Div Yield
ROE
Debt/Equity
52W Range
$2 – $14

XBIO Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

10-Year Performance Revenue, net income, margins and EPS trends

Revenue & Net Income $3M
10-point trend, -0.8%
2016-12-31 2025-12-31
EPS $-1.58
5-point trend, -187.3%
2021-12-31 2025-12-31
Free Cash Flow
Margins

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric
5Y trend
XBIO
Peer Median
P/E (TTM)
5-point trend, +94.1%
-1.4

Profitability Gross, operating and net margins; ROE, ROA, ROIC

Metric
5Y trend
XBIO
Peer Median

Financial Health Debt, liquidity, solvency — balance sheet strength

Metric
5Y trend
XBIO
Peer Median

Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR

Metric
5Y trend
XBIO
Peer Median
Revenue YoY
5-point trend, +156.4%
19.0%
Revenue CAGR 3Y
5-point trend, +156.4%
20.4%
Revenue CAGR 5Y
5-point trend, +156.4%
46.8%

Per Share Metrics EPS, book value per share, cash flow per share, dividend per share

Metric
5Y trend
XBIO
Peer Median
EPS (Diluted)
5-point trend, -187.3%
$-1.58

Capital Efficiency Asset turnover, inventory turnover, receivables turnover

Metric
5Y trend
XBIO
Peer Median

XBIO Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

SELL 6 analysts
  • Strong Buy 0 0.0%
  • Buy 0 0.0%
  • Hold 3 50.0%
  • Sell 1 16.7%
  • Strong Sell 2 33.3%

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

Avg Surprise
-0.07%
Period EPS Actual EPS Est Surprise
June 30, 2025 $-0.45 $-0.65 0.20%
March 31, 2025 $-0.59 $-0.73 0.14%
Dec. 31, 2024 $-0.68 $-0.20 -0.48%
Sept. 30, 2024 $-0.28 $-0.14 -0.14%

Peer comparison (GICS sub-industry) Key metrics vs sector peers

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
XBIO -1.4 19.0%
BOLT $11M -0.3 0.07% -433.7% -102.2%
CDIO
ACXP $6M -0.5 -180.3%
PMCB $8M -0.3 -56.7%
BRTX $10M -0.7 -10.3% -3959.4% -547.6% 93.4%
DRMA
GOVX $296.2K -37.1% -862.3% -645.9%
LABT
BCAB -0.6

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

Income Statement 17
Annual Income Statement data for XBIO
Metric Trend 202520242023202220212020201920182017201620152014
Revenue 12-point trend, +2976411.00 $3M $3M $3M $2M $1M $436.9K $17.1K $0 $8M $3M $0 $0
Cost of Revenue · · · · · · · · · · · $0
Gross Profit · · · · · · · · · · · $0
R&D Expense 12-point trend, -51.5% $3M $3M $3M $5M $3M $2M $5M $3M $4M $44M $3M $6M
SG&A Expense 12-point trend, -58.4% $3M $3M $4M $4M $4M $3M $5M $4M $7M $7M $6M $7M
Operating Expenses 9-point trend, -55.0% $6M $7M $7M $8M $7M $14M $13M $7M · · · $13M
Operating Income 12-point trend, +78.1% $-3M $-4M $-5M $-7M $-6M $-14M $-13M $-7M $-4M $-47M $-10M $-13M
Interest Expense 4-point trend, -61.4% · · · · · · · · $1.8K $729.6K $267.0K $4.7K
Interest Income · · · · · · · · · · · $19.0K
Other Non-op 12-point trend, +101.8% $5.7K $-5.7K $25.4K $-1.6K $1.1K $-492 $3.3K $-24.6K $-24.6K $-85.4K $-235.4K $-326.9K
Pretax Income · · · · · · · · · · · $-14M
Income Tax 12-point trend, +0.00 $0 $0 $0 $0 $0 $-3M $0 $0 $0 $0 $0 $0
Net Income 12-point trend, +81.3% $-3M $-4M $-4M $-7M $-6M $-11M $-13M $-7M $-4M $-54M $-13M $-14M
EPS (Basic) 5-point trend, -187.3% $-1.58 $-2.57 $-2.71 $-4.61 $-0.55 · · · · · · ·
EPS (Diluted) 5-point trend, -187.3% $-1.58 $-2.57 $-2.71 $-4.61 $-0.55 · · · · · · ·
Shares (Basic) 5-point trend, -83.4% 1,701,571 1,541,339 1,528,210 1,422,443 10,279,408 · · · · · · ·
Shares (Diluted) 5-point trend, -83.4% 1,701,571 1,541,339 1,528,210 1,422,443 10,279,408 · · · · · · ·
Balance Sheet 25
Annual Balance Sheet data for XBIO
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +214.4% $8M $6M $9M $13M $18M $12M $10M $571.6K $6M $4M $132.2K $3M
Receivables 3-point trend, +0.00 · · · · · · · · $0 $3M $0 ·
Prepaid Expense 12-point trend, -18.5% $166.3K $422.0K $603.8K $556.1K $479.4K $842.0K $722.1K $555.9K $285.0K $1M $247.3K $204.0K
Current Assets 12-point trend, +189.8% $8M $7M $10M $14M $19M $12M $11M $1M $6M $8M $4M $3M
PP&E (Net) 9-point trend, -100.0% · · · $0 $0 $0 $757 $5.0K $27.8K $42.4K $62.0K $119.4K
PP&E (Gross) 9-point trend, -100.0% · · · $0 $50.2K $57.0K $57.0K $89.4K $358.3K $349.1K $332.3K $586.1K
Accum. Depreciation 9-point trend, -100.0% · · · $0 $50.2K $57.0K $56.3K $84.4K $330.5K $306.7K $270.2K $466.7K
Goodwill 7-point trend, -100.0% · · · · · $0 $9M $3M $3M $3M $3M $3M
Other Non-current Assets 12-point trend, +57.5% $313.9K $313.9K $1M $1M $1M $810.0K $1M $705.7K $724.7K $66.3K $129.3K $199.3K
Total Assets 12-point trend, -48.7% $8M $7M $11M $15M $20M $13M $22M $14M $19M $21M $17M $16M
Accounts Payable 12-point trend, -69.7% $258.1K $283.6K $240.8K $287.4K $362.5K $327.4K $931.1K $934.1K $786.8K $1M $2M $852.8K
Accrued Liabilities 12-point trend, -49.6% $709.9K $610.6K $568.8K $785.8K $1M $574.0K $464.0K $664.0K $1M $838.9K $1M $1M
Current Liabilities 12-point trend, -64.1% $968.0K $894.3K $809.6K $1M $1M $936.9K $1M $2M $2M $2M $7M $3M
Capital Leases 2-point trend, +27043.00 · · · · · $27.0K $0 · · · · ·
Deferred Tax 7-point trend, -99.1% · · · · · $27.0K $3M $3M $3M $3M $3M $3M
Other Non-current Liabilities 5-point trend, -100.0% · · · · · · · $0 $0 $19.9K $38.8K $56.4K
Total Liabilities 12-point trend, -83.4% $968.0K $894.3K $809.6K $1M $1M $964.0K $4M $5M $5M $5M $10M $6M
Common Stock 12-point trend, -98.5% $2.3K $1.5K $1.5K $1.5K $13.5K $8.8K $6.1K $811 $9.0K $8.7K $4.9K $150.0K
Paid-in Capital 12-point trend, +134.2% $212M $208M $208M $208M $206M $194M $188M $168M $165M $164M $100M $91M
Retained Earnings 12-point trend, -164.3% $-200M $-197M $-193M $-189M $-183M $-177M $-166M $-153M $-146M $-142M $-88M $-76M
Treasury Stock Flat — no change across 12 periods $5M $5M $5M $5M $5M $5M $5M $5M $5M $5M $5M $5M
AOCI 12-point trend, -55.9% $253.7K $253.7K $253.7K $253.7K $253.7K $253.7K $253.7K $253.7K $253.7K $253.7K $253.7K $575.7K
Stockholders' Equity 12-point trend, -29.4% $7M $6M $10M $14M $18M $12M $17M $10M $14M $16M $7M $10M
Liabilities + Equity 12-point trend, -48.7% $8M $7M $11M $15M $20M $13M $22M $14M $19M $21M $17M $16M
Shares Outstanding 12-point trend, -98.4% 2,291,056 1,542,139 1,540,684 1,516,659 13,439,612 8,745,207 6,065,441 783,865 8,717,541 4,585,800 4,585,800 139,297,282
Cash Flow 8
Annual Cash Flow data for XBIO
Metric Trend 202520242023202220212020201920182017201620152014
D&A 5-point trend, -100.0% · · · $0 $0 $1.0K · · · · $56.1K $88.7K
Stock-based Comp 12-point trend, -95.7% $64.8K $171.8K $283.1K $511.5K $410.4K $468.9K $806.1K $1M $2M $2M $2M $2M
Operating Cash Flow 12-point trend, +82.0% $-2M $-3M $-4M $-5M $-5M $-4M $-6M $-6M $1M $-9M $-5M $-13M
CapEx 5-point trend, -100.0% · · · · · · · $0 $9.3K $16.8K $1.7K $57.7K
Investing Cash Flow 8-point trend, +100.0% · · $0 $-500.0K $0 $0 $2.0K $22.5K $-9.3K $-16.8K · ·
Stock Issued 8-point trend, -60.0% $4M $0 · $0 $11M $5M $0 · · · $0 $10M
Financing Cash Flow 9-point trend, -68.5% $4M $0 · $0 $11M $5M $16M $1M $0 $13M · ·
Taxes Paid · · · · · · · · · · · $0
Per Share 1
Annual Per Share data for XBIO
Metric Trend 202520242023202220212020201920182017201620152014
EPS (TTM) 5-point trend, -187.3% $-1.58 $-2.57 $-2.71 $-4.61 $-0.55 · · · · · · ·
Growth Rates 3
Annual Growth Rates data for XBIO
Metric Trend 202520242023202220212020201920182017201620152014
Revenue YoY 5-point trend, -88.5% 19.0% -1.6% 48.8% 47.1% 165.6% · · · · · · ·
Revenue CAGR 3Y 3-point trend, -74.5% 20.4% 29.1% 79.8% · · · · · · · · ·
Revenue CAGR 5Y 46.8% · · · · · · · · · · ·
Valuation (TTM) 5
Annual Valuation (TTM) data for XBIO
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +2976411.00 $3M $3M $3M $2M $1M $436.9K $17.1K $0 $8M $3M $0 $0
Net Income TTM 12-point trend, +81.3% $-3M $-4M $-4M $-7M $-6M $-11M $-13M $-7M $-4M $-54M $-13M $-14M
P/E 5-point trend, +94.1% -1.4 -1.6 -1.3 -0.6 -23.5 · · · · · · ·
P / Tangible Book 6-point trend, -95.4% 0.7 1.0 0.5 3.2 9.4 14.6 · · · · · ·
Earnings Yield 5-point trend, -1609.2% -72.8% -64.4% -78.5% -161.8% -4.3% · · · · · · ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

Income Statement
2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $3M$3M$3M$2M$1M
Net Income $-3M$-4M$-4M$-7M$-6M
Diluted EPS $-1.58$-2.57$-2.71$-4.61$-0.55

My Metrics Your personal watchlist — selected rows from Full Fundamentals

📊

Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Institutional owners (13F) 8 filers · $422K total · As of June 30, 2026

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
3 (+3 vs prior Q) 0 (-5 vs prior Q) 0 (-1 vs prior Q) 3 (+1 vs prior Q) -10K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
RENAISSANCE TECHNOLOGIES LLC $341,750 117,440 80.90% Shares
GEODE CAPITAL MANAGEMENT, LLC $38,388 13,184 9.09% Shares
VANGUARD CAPITAL MANAGEMENT LLC $36,902 12,681 8.74% Shares
SBI Securities Co., Ltd. $2,910 1,000 0.69% Shares
Tower Research Capital LLC (TRC) $2,025 696 0.48% Shares
MORGAN STANLEY $437 150 0.10% Shares
JTC Employer Solutions Trustee Ltd $8 2,700 0.00% Shares
Darwin Wealth Management, LLC $5 2 0.00% Shares

Company insiders 1 insider · 1 officers · 0 directors

Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
James F Parslow Chief Financial Officer April 3, 2017 A 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

Activists & 5%+ owners 3 positions

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
CLS Therapeutics, LLC, CLS Therapeutics Ltd., Dmitry Genkin, Victor Tets, Georgy Tets, M. Scott Maguire ×3 filings March 18, 2024 Initial filing SEC
PJSC Pharmsynthez, LLC SynBio, Dmitry Genkin July 13, 2017 Initial filing SEC
Michael Scott Maguire Nov. 22, 2016 Initial filing SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ETF ownership Held by 1 ETF

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
VXF · VANGUARD INDEX FUNDS 0.00% 12,681 SH Aug. 8, 2026 Daily